AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating restated by research analysts at J P Morgan Chase & Co in a research note issued to investors on Friday.

A number of other equities research analysts also recently issued reports on AZN. UBS AG set a GBX 5,150 ($66.51) price objective on shares of AstraZeneca plc and gave the stock a “neutral” rating in a research note on Tuesday, June 27th. Barclays PLC reiterated an “overweight” rating and set a GBX 5,500 ($71.03) price objective on shares of AstraZeneca plc in a research note on Monday, August 7th. Jefferies Group LLC reduced their price objective on shares of AstraZeneca plc from GBX 4,900 ($63.28) to GBX 4,400 ($56.83) and set a “hold” rating on the stock in a research note on Tuesday, August 1st. Investec upgraded shares of AstraZeneca plc from a “hold” rating to a “buy” rating and reduced their price objective for the stock from GBX 5,000 ($64.57) to GBX 4,900 ($63.28) in a research note on Wednesday, August 9th. Finally, Deutsche Bank AG reiterated a “buy” rating and set a GBX 5,300 ($68.45) price objective on shares of AstraZeneca plc in a research note on Tuesday. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company. AstraZeneca plc has an average rating of “Hold” and a consensus target price of GBX 4,930.64 ($63.68).

AstraZeneca plc (AZN) traded up 0.34% during trading on Friday, reaching GBX 4790.00. 2,138,652 shares of the company’s stock were exchanged. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00. The firm’s market cap is GBX 60.64 billion. The stock’s 50 day moving average price is GBX 4,593.39 and its 200 day moving average price is GBX 4,871.66.

AstraZeneca plc (LON:AZN) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $1.01. AstraZeneca plc had a net margin of 8.83% and a return on equity of 14.36%. Equities research analysts anticipate that AstraZeneca plc will post $3.75 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “AstraZeneca plc (AZN) Given “Neutral” Rating at J P Morgan Chase & Co” was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/09/09/astrazeneca-plc-azn-given-neutral-rating-at-j-p-morgan-chase-co.html.

In other news, insider Nazneen Rahman purchased 39 shares of the stock in a transaction on Thursday, July 27th. The stock was purchased at an average price of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.